top of page

BioLargo to Present at the Rodman & Renshaw 16th Annual Global Investment Conference

SANTA ANA, CA-(August 20, 2014) – BioLargo, Inc. (OTCQB: BLGO) will present at the Rodman & Renshaw 16th Annual Global Investment Conference on Tuesday, September 9th at the New York Palace Hotel. Dennis Calvert, BioLargo’s president, is scheduled to present at 2:55 p.m. ET.

A webcast of the live presentation will be available at where it will be retained for 90 days. A copy of the slides management will be presenting will also be available on the company’s website.

UPDATE: To register for the Rodman & Renshaw 16th Annual Global Investment Conference Webcast, click the following link:

If you are interested in a meeting with management, please contact your Rodman & Renshaw representative or you may call BioLargo’s investor relations firm, LHA, at 415-433-3777.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB: BLGO) makes life better by delivering technology-based products that help solve some of the world’s most important problems that threaten water, food, agriculture, healthcare and energy. More information can be found about the company and its subsidiaries at The subsidiary BioLargo Water, Inc. ( showcases the Advanced Oxidation Systems, including its AOS Filter, a product in development specifically designed to eliminate common, troublesome, and dangerous (toxic) contaminants in water in a fraction of the time and cost of current technologies. BioLargo also owns a 50% interest in the Isan System, which was honored with a “Top 50 Water Company for the 21st Century” award by the Artemis Project. The subsidiary Odor-No-More Inc., features award-winning products serving the pet, equine, and consumer markets, including the Nature’s Best Solution® and Deodorall® brands. ( The subsidiary Clyra Medical Technologies, Inc. (, focuses on advanced wound care management and is preparing to make FDA 510(k) applications in 2015.

Safe Harbor Statement

The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo’s current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo’s Annual Report on Form 10-K for the year ended December 31, 2013.

Investor Contact: Becky Herrick, LHA 415.433.3777,

Recent Posts

See All


bottom of page